Start-Up Previews (2/04)
Executive SummaryA preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Rediscovering Existing Drugs, features profiles of Ascend Therapeutics Inc., Ocularis Pharma Inc. and Oriel Therapeutics Inc. Plus these Start-Ups Across Health Care: Exagen Diagnostics Inc., Piedmont Pharmaceuticals LLC, Protein Forest Inc., Proteus Biomedical Inc. and Xilas Medical Inc.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.